Piper Sandler downgraded Cerevel Therapeutics (CERE) to Neutral from Overweight with a price target of $45, up from $33, after AbbVie (ABBV) announced it plans to acquire Cerevel for $45.00 per share. The firm says the transaction validates its bullish thinking on the transformative potential of the selective muscarinic agonist class.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERE:
- M & A News: AbbVie (NYSE:ABBV) Doubles Down on Acquisitions, Buys CERE for $8.7B
- AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
- Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
- Cerevel Therapeutics reinstated with a Neutral at JPMorgan
- Cerevel Therapeutics to Present at Upcoming Investor Conferences
